All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @_hunsky_ on TikTok · 94s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @_hunsky_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Alright, so I'm about to start IGF-1 LR3.
  2. 0:03If you all have been following, you know, I've been doing RETA.
  3. 0:06Had a crazy transformation, but now we're going to be documenting kind of what IGF-1 LR3 is,
  4. 0:12kind of what to expect and how it works.
  5. 0:15This is my starting physique right now, I would say.
  6. 0:21With IGF, you're going to be injecting for research purposes only 5 to 10 units.
  7. 0:28I reconstitute with 2 milliliters and a 1 milligram vial, so that's going to be 25 to 50 micrograms per injection.
  8. 0:35Obviously you need to clean it.
  9. 0:37Now this one's going to burn a little bit.
  10. 0:47You reconstitute with acidic acid, not bacterial static water, so because of that it does burn.
  11. 0:5420, 30 seconds, not too bad.
  12. 0:57And that's it.
  13. 1:00Rub it out a little bit.
  14. 1:02Expect great pumps, expect accelerated muscle growth and recover.
  15. 1:07Great sleep, your cover amazing.
  16. 1:09So all really good things.
  17. 1:11I'll keep you all updated throughout my journey.
  18. 1:16Also really important to know the FDA is really cracking down on access to peptide.
  19. 1:22So if IGF-1 LR3 or any other type of peptide is something you would be interested in, I would suggest making that decision soon
  20. 1:30because that option is about to be taken away from you most likely.

IGF-1 LR3 on TikTok: what the gym crowd gets wrong

_hunsky_

TikTok creator

81.8K viewsWatch on TikTok

Quick answer

IGF-1 LR3 is a synthetic long-acting analog of insulin-like growth factor 1, used experimentally for its anabolic and recovery-related properties, but it has no FDA-approved human indication and lacks controlled clinical trial data for the muscle growth and sleep benefits the creator describes. The creator reconstitutes at 500 mcg/mL in acetic acid and administers 25 to 50 mcg subcutaneously, which aligns with commonly circulated self-administration protocols, though no peer-reviewed dose-finding study in healthy humans supports this range. Key unmentioned risks include hypoglycemia risk, potential mitogenic effects in individuals with undetected neoplasms, and the absence of quality assurance in research-grade peptide supply chains.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For IGF-1 LR3 on TikTok: what the gym crowd gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

IGF-1 LR3 on TikTok: what the gym crowd gets wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "IGF-1 LR3 on TikTok: what the gym crowd gets wrong" from _hunsky_. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: IGF-1 LR3 is a synthetic long-acting analog of insulin-like growth factor 1, used experimentally for its anabolic and recovery-related properties, but it has no FDA-approved human indication and lacks controlled clinical trial data for the muscle growth and sleep benefits the creator describes.

The reason this review is not generic is the source wording and the canonical claim label "peptides what to expect with igf1 lr3 for research purposes only pept." In this clip, the useful excerpt is: "Alright, so I'm about to start IGF-1 LR3." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Fryburg et al.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

IGF-1 LR3 is a synthetic long-acting analog of insulin-like growth factor 1, used experimentally for its anabolic and recovery-related properties, but it has no FDA-approved human indication and lacks controlled clinical trial data for the muscle growth and sleep benefits the creator describes.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • IGF-1 LR3 is a synthetic long-acting analog of insulin-like growth factor 1, used experimentally for its anabolic and recovery-related properties, but it has no FDA-approved human indication and lacks controlled clinical trial data for the muscle growth and sleep benefits the creator describes. The creator reconstitutes at 500 mcg/mL in acetic acid and administers 25 to 50 mcg subcutaneously, which aligns with commonly circulated self-administration protocols, though no peer-reviewed dose-finding study in healthy humans supports this range. Key unmentioned risks include hypoglycemia risk, potential mitogenic effects in individuals with undetected neoplasms, and the absence of quality assurance in research-grade peptide supply chains.
  • IGF-1 LR3 has no FDA-approved human indication; it is classified as a research chemical with no regulatory oversight on purity or concentration in commercial vials.
  • Fryburg et al. (1995, American Journal of Physiology) confirmed IGF-1 increases muscle protein synthesis locally in humans, but this was with native IGF-1 via controlled infusion, not subcutaneous LR3 injections.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • IGF-1 LR3 has no FDA-approved human indication; it is classified as a research chemical with no regulatory oversight on purity or concentration in commercial vials.
  • Fryburg et al. (1995, American Journal of Physiology) confirmed IGF-1 increases muscle protein synthesis locally in humans, but this was with native IGF-1 via controlled infusion, not subcutaneous LR3 injections.
  • The acetic acid reconstitution advice in this video is technically correct and more accurate than many similar videos that suggest bacteriostatic water.
  • IGF-1 receptor activation has mitogenic properties; Kopchick and Laron (1999, Molecular Genetics and Metabolism) reviewed evidence linking IGF-1 axis dysregulation to tumor promotion, a risk never mentioned in the video.
  • Hypoglycemia is a documented acute risk of exogenous IGF-1 administration due to insulin-like receptor activity, and this video provides no safety guidance on that risk.
  • The FDA's 2024 compounding policy revisions did restrict several peptides, but IGF-1 LR3 was never on an approved compounding list to begin with, making the "access being taken away" framing somewhat misleading.
  • Self-administration of unregulated injectable compounds without baseline lab work, including serum IGF-1 levels and metabolic panels, removes any ability to monitor for adverse hormonal or metabolic effects.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @_hunsky_ actually say?

The creator demonstrated a subcutaneous injection of IGF-1 LR3, reconstituted in acetic acid at a concentration of 25 to 50 micrograms per dose, and promised viewers "great pumps," "accelerated muscle growth," and "amazing" sleep and recovery. They also issued what amounts to a soft sales pitch wrapped in urgency: get it now before the FDA locks access down.

To be fair, they did say "for research purposes only" repeatedly, which is the standard legal disclaimer you hear in this corner of the internet. But then they immediately pivoted to personal use, on-camera injection, and outcome claims. The "research purposes" framing does not hold up when you are filming yourself injecting and cataloguing your physique transformation. That disclaimer is cosmetic, not substantive.

The creator was previously using something called "RETA," likely retatrutide, a GLP-1/GIP/glucagon receptor tri-agonist, and is now transitioning to IGF-1 LR3. That stacking context matters and is mostly glossed over here.

Does the science back this up?

The anabolic effects of IGF-1 are real and reasonably well-documented in preclinical research, but the leap from rodent studies to "expect accelerated muscle growth" in healthy humans is a significant one. The human data on IGF-1 LR3 specifically is thin to nonexistent in peer-reviewed literature.

IGF-1, in general, is a potent growth factor. Endogenous IGF-1 mediates much of growth hormone's anabolic signaling through the PI3K/Akt/mTOR pathway, which does drive muscle protein synthesis. Fryburg et al. (1995, American Journal of Physiology) showed that local IGF-1 infusion increased forearm muscle protein synthesis in humans. That is real. But LR3 is a synthetic analog engineered to have reduced binding to IGF-binding proteins, extending its half-life to roughly 20 to 30 hours compared to native IGF-1's minutes. Almost no controlled human trials exist on LR3 specifically as an intramuscular or subcutaneous performance agent.

The sleep quality claim has no direct supporting evidence for IGF-1 LR3 at the doses described. GH secretagogues can improve slow-wave sleep, but that is a different mechanism entirely.

What did they get wrong (or right)?

The acetic acid reconstitution advice is actually correct. IGF-1 LR3 is poorly soluble in bacteriostatic water and is typically reconstituted in 0.1 to 1% acetic acid solution. The burning is a real and expected consequence. Credit where it is due: that is accurate and practical information that many similar videos get wrong.

The dose math also checks out. Two milliliters reconstituting a 1 milligram vial gives 500 micrograms per milliliter. At 5 to 10 units on an insulin syringe (where 1 unit equals 10 microliters), that yields 25 to 50 micrograms. The arithmetic is right.

What is misleading is the blanket promise of outcomes. "Expect great pumps, expect accelerated muscle growth" is stated as settled fact. The human evidence does not support that certainty. More seriously, IGF-1 LR3 carries real risks that go unmentioned: hypoglycemia, potential promotion of existing subclinical tumors, and acromegalic effects with prolonged use. Kopchick and Laron (1999, Molecular Genetics and Metabolism) reviewed IGF-1 axis dysregulation and its associations with cancer proliferation. That omission is irresponsible in an 81,000-view video.

What should you actually know?

IGF-1 LR3 is not FDA-approved for human use in any context. It is sold as a research chemical, meaning quality control, sterility, and actual peptide content are not regulated. You have no guarantee that what is in the vial is what the label claims.

The FDA crackdown the creator references is real. The 2024 CPG revision and ongoing enforcement actions have restricted compounded peptides, and LR3 specifically is not on any approved compounding list. This is not a manufactured panic; it reflects genuine regulatory movement. But framing it as "make your decision soon" is classic urgency-based marketing, not education.

If you are interested in peptide therapy through a legitimate channel, the only responsible path is through a licensed provider who can assess your baseline IGF-1 levels, health history, and risk profile before any intervention. Self-injecting unregulated compounds based on a TikTok tutorial carries risks this video does not acknowledge.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

_hunsky_ · TikTok creator

81.8K views on this video

What to expect with igf1-lr3 for research purposes only. #peptide #educational #fittok #gym #workout

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about igf-1 lr3 has no fda-approved human indication; it?

IGF-1 LR3 has no FDA-approved human indication; it is classified as a research chemical with no regulatory oversight on purity or concentration in commercial vials.

What does the video say about fryburg et al. (1995, american journal of physiology) confirmed igf-1?

Fryburg et al. (1995, American Journal of Physiology) confirmed IGF-1 increases muscle protein synthesis locally in humans, but this was with native IGF-1 via controlled infusion, not subcutaneous LR3 injections.

What does the video say about the acetic acid reconstitution advice in this video?

The acetic acid reconstitution advice in this video is technically correct and more accurate than many similar videos that suggest bacteriostatic water.

What does the video say about igf-1 receptor activation has mitogenic properties; kopchick?

IGF-1 receptor activation has mitogenic properties; Kopchick and Laron (1999, Molecular Genetics and Metabolism) reviewed evidence linking IGF-1 axis dysregulation to tumor promotion, a risk never mentioned in the video.

What does the video say about hypoglycemia?

Hypoglycemia is a documented acute risk of exogenous IGF-1 administration due to insulin-like receptor activity, and this video provides no safety guidance on that risk.

What does the video say about the fda's 2024 compounding policy revisions did restrict several peptides,?

The FDA's 2024 compounding policy revisions did restrict several peptides, but IGF-1 LR3 was never on an approved compounding list to begin with, making the "access being taken away" framing somewhat misleading.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by _hunsky_, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.